Neurofibromatosis type 1 secondary prevention: Difference between revisions
Jump to navigation
Jump to search
MoisesRomo (talk | contribs) No edit summary |
MoisesRomo (talk | contribs) No edit summary |
||
| Line 4: | Line 4: | ||
==Overview== | ==Overview== | ||
'''[[Neurofibromatosis type 1]]''' has a wide range of commorbidities, regular multidisciplinary follow-ups are mandatory. | '''[[Neurofibromatosis type 1]]''' has a wide range of commorbidities, regular multidisciplinary follow-ups are mandatory. Annual [[mammogram]] and [[Eye examination|ophtalmologic examination]] should be made in patients with [[neurofibromatosis type 1]]. [[Neurocognitive]] evaluation and [[blood pressure]] measurements should be done regularly to record evolution and detect secondary causes of impairment. | ||
Annual [[mammogram]] and [[Eye examination|ophtalmologic examination]] should be made in patients with [[neurofibromatosis type 1]]. | |||
[[Neurocognitive]] evaluation and [[blood pressure]] measurements should be done regularly to record evolution and detect secondary causes of impairment. | |||
==Secondary Prevention== | ==Secondary Prevention== | ||
* [[Blood pressure]] should be measured routinely, including during [[Child development|childhood]].Secondary causes of [[hypertension]] should be ruled out, including [[Multiple endocrine neoplasia type 2|MEN 2B]].<ref name="pmid31582003">{{cite journal |vauthors=Ly KI, Blakeley JO |title=The Diagnosis and Management of Neurofibromatosis Type 1 |journal=Med. Clin. North Am. |volume=103 |issue=6 |pages=1035–1054 |date=November 2019 |pmid=31582003 |doi=10.1016/j.mcna.2019.07.004 |url=}}</ref> | *[[Blood pressure]] should be measured routinely, including during [[Child development|childhood]].Secondary causes of [[hypertension]] should be ruled out, including [[Multiple endocrine neoplasia type 2|MEN 2B]].<ref name="pmid31582003">{{cite journal |vauthors=Ly KI, Blakeley JO |title=The Diagnosis and Management of Neurofibromatosis Type 1 |journal=Med. Clin. North Am. |volume=103 |issue=6 |pages=1035–1054 |date=November 2019 |pmid=31582003 |doi=10.1016/j.mcna.2019.07.004 |url=}}</ref> | ||
* Complete [[Eye examination|ophtalmologic examination]] should be made annualy throughout adulthood or until 25 years of diagnosis to evaluate [[OPG]]. [[Slit lamp]] evaluation for [[Lisch nodule|Lisch nodules]] is made only once for confirmation of diagnosis.<ref name="pmid31582003" /> | *Complete [[Eye examination|ophtalmologic examination]] should be made annualy throughout adulthood or until 25 years of diagnosis to evaluate [[OPG]]. [[Slit lamp]] evaluation for [[Lisch nodule|Lisch nodules]] is made only once for confirmation of diagnosis.<ref name="pmid31582003" /> | ||
* Patients with [[neurofibromatosis type 1]] should have regular [[DEXA scan]] follow-ups.<ref name="pmid31582003" /> | *Patients with [[neurofibromatosis type 1]] should have regular [[DEXA scan]] follow-ups.<ref name="pmid31582003" /> | ||
* [[Neurocognitive deficit|Neurocognitive]] evaluation should be done at a regular basis to test evolution.<ref name="pmid31582003" /> | *[[Neurocognitive deficit|Neurocognitive]] evaluation should be done at a regular basis to test evolution.<ref name="pmid31582003" /> | ||
* Annual [[mammogram]] starting at age 30 should be made in patients with [[neurofibromatosis type 1]] to screen breast cancer. [[Breast cancer]] should be managed agressively in these patients, considering bilateral mastectomy. <ref name="pmid31582003" /> | *Annual [[mammogram]] starting at age 30 should be made in patients with [[neurofibromatosis type 1]] to screen breast cancer. [[Breast cancer]] should be managed agressively in these patients, considering bilateral mastectomy. <ref name="pmid31582003" /> | ||
* [[Calcium]] and [[vitamin D]] supplementation are rugularly prescribed to prevent [[osteoporosis]] and [[Osteoporosis|osteopenia]].<ref name="pmid315820032">{{cite journal |vauthors=Ly KI, Blakeley JO |title=The Diagnosis and Management of Neurofibromatosis Type 1 |journal=Med. Clin. North Am. |volume=103 |issue=6 |pages=1035–1054 |date=November 2019 |pmid=31582003 |doi=10.1016/j.mcna.2019.07.004 |url=}}</ref> | *[[Calcium]] and [[vitamin D]] supplementation are rugularly prescribed to prevent [[osteoporosis]] and [[Osteoporosis|osteopenia]].<ref name="pmid315820032">{{cite journal |vauthors=Ly KI, Blakeley JO |title=The Diagnosis and Management of Neurofibromatosis Type 1 |journal=Med. Clin. North Am. |volume=103 |issue=6 |pages=1035–1054 |date=November 2019 |pmid=31582003 |doi=10.1016/j.mcna.2019.07.004 |url=}}</ref> | ||
==References== | ==References== | ||
Latest revision as of 16:47, 1 September 2020
|
Neurofibromatosis type 1 Microchapters |
|
Differentiating Neurofibromatosis type 1 from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Neurofibromatosis type 1 secondary prevention On the Web |
|
American Roentgen Ray Society Images of Neurofibromatosis type 1 secondary prevention |
|
Risk calculators and risk factors for Neurofibromatosis type 1 secondary prevention |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Moises Romo M.D.
Overview
Neurofibromatosis type 1 has a wide range of commorbidities, regular multidisciplinary follow-ups are mandatory. Annual mammogram and ophtalmologic examination should be made in patients with neurofibromatosis type 1. Neurocognitive evaluation and blood pressure measurements should be done regularly to record evolution and detect secondary causes of impairment.
Secondary Prevention
- Blood pressure should be measured routinely, including during childhood.Secondary causes of hypertension should be ruled out, including MEN 2B.[1]
- Complete ophtalmologic examination should be made annualy throughout adulthood or until 25 years of diagnosis to evaluate OPG. Slit lamp evaluation for Lisch nodules is made only once for confirmation of diagnosis.[1]
- Patients with neurofibromatosis type 1 should have regular DEXA scan follow-ups.[1]
- Neurocognitive evaluation should be done at a regular basis to test evolution.[1]
- Annual mammogram starting at age 30 should be made in patients with neurofibromatosis type 1 to screen breast cancer. Breast cancer should be managed agressively in these patients, considering bilateral mastectomy. [1]
- Calcium and vitamin D supplementation are rugularly prescribed to prevent osteoporosis and osteopenia.[2]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 Ly KI, Blakeley JO (November 2019). "The Diagnosis and Management of Neurofibromatosis Type 1". Med. Clin. North Am. 103 (6): 1035–1054. doi:10.1016/j.mcna.2019.07.004. PMID 31582003.
- ↑ Ly KI, Blakeley JO (November 2019). "The Diagnosis and Management of Neurofibromatosis Type 1". Med. Clin. North Am. 103 (6): 1035–1054. doi:10.1016/j.mcna.2019.07.004. PMID 31582003.